Twelve hypopituitary patients ranging in age from 58f2 to 15 ?fa years were treated for 12 months with a standardized dose of human growth hormone (HGH), 0.1 or 0.05 U/kg three times weekly). From the 7th to 12th month inclusive, fluoxymesterone, 2.5 mg/m2/24 hr per os was given in combination with the growth hormone. From the 12th to the 18th month, no therapy was given. Heights and weights were recorded every 1 or 2 months. Bone age films were assessed at the onset and again in the 6th, 12th, and 18th month of the study.
Introduction
induced hypoglycemia and intravenous L-arginine (0.5 Long term treatment of hypopituitary patients with H G H is associated with declining rates of linear growth [l, 2, 141, which necessitate prolongation of the treatment period, the use of larger doses of HGH, and a delay in the attainment of normal height. Although there is sound experimental proof of synergism between growth hormone and androgen [13, 15, 161 , the combined use of these hormones i n children with hypopituitarism has not been generally recommended because of the risk of accelerating bone maturation.
T h e purpose of this study was to determine if the linear growth responses of patients with hypopituitarism who received H G H might be enhanced by the simultaneous administration of androgen without jeopardizing the attainment of normal adult height defined as height in excess of 5 feet. T h e effectiveness and safety of the treatment regimens were evaluated by comparison of the rates of linear growth, weight gain, and bone maturation in three consecutive 6-month periods during which time the patients received H G H alone, HGH-androgen combination, and n o treatment, respectively.
Methods and Materials
Twelve hypopituitary patients, nine males and three females, whose ages ranged from 58/,, to 157/,, years entered the study. T h e three girls had isolated HGH deficiency and exhibited early signs of pubertal development but had not reached their menarche. Of the nine boys, five were prepubertal i n age, and their gonadotropin levels could not be meaningfully assessed. T h e remaining four boys were beyond 14 years of age, manifested no sexual development and had prepubertal levels of gonadotropins in plasma and urine. Two of the boys had organic disease in the pituitary hypothalamic area. One boy had received a serious head injury during infancy and required USP thyroid, 90 mg/m2/24 hr. T h e other boy had a craniopharyngioma which caused deficiencies of adrenocorticotropic, thyroid-stimulating, follicle-stimulating, and luteinizing hormones and vasopressin. In addition to the treatment protocol, he received cortisone, 5 mg/ m2/24 hr, USP thyroid, 90 mg/m2/24 hr, and vasopressin. H e was the only child in the group who required cortisone replacement.
T h e diagnosis of H G H deficiency was confirmed on the basis of abnormal plasma H G H concentrations (peak <4 ng/ml) following stimulation with insuling/kg) administered separately on 2 sepaEate days.
Plasma H G H concentrations were measured by the double antibody radioimmunoassay method [5, 121. T h e linear growth rate of all the patients before H G H replacement was less than 4 cm/year. Among the 12 children, retardation i n bone maturation varied from 3 to 8 years below chronologic age.
T h e treatment protocol consisted of HGH, 0.05 or 0.1 U/kg, administered intramuscularly three times weekly for the first 6 months. Only one child received the 0.05 U/kg dose. T h e remaining 11 patients were given 0.1 U/kg HGH. I n the second 6-month period of the study, the standardized dose of H G H was continued in combination with fluoxymesterone, 2.5 mg/m2/ 24 hr per os, administered twice daily. I n the third 6-month period, H G H and androgen were discontinued. Throughout the 18 months of study, heights and weights were recorded every 1 or 2 months, and roentgenogram of the left hand and wrist was obtained at 0, 6, 12, and 18 months. Interpretation of bone age was performed by one radiologist (RM) who was not informed of the treatment schedule. T h e Gruelich and Pyle [6] standards were used to estimate bone age.
T h e differences in the rates of linear growth, weight gain and bone maturation during the three consecutive 6-month study periods were analyzed for statistical significance by means of the t test for paired samples.
Results
Data for the individual patients are given in Table I . Figure 1 depicts the linear growth rate in centimeters per year in each study period. During the first 6 months of H G H treatment, the mean growth rate in centimeters per year +-SD was 9.4 r+-2.3, and the range was 6-14 cm/year. T e n children grew at rates exceeding 8 cm/year, and five grew in excess of 10 cm/year. No child who entered the study was disqualified because of a poor response to H G H treatment.
Linear Growth Response
During the second 6-month period when H G H and fluoxymesterone were administered simultaneously, the mean growth rate was 13.4 cm/year + SD 3.0 and a range of 8.4-17 cm/year. T e n children grew at rates exceeding 10 cm/year. No child showed a decline in growth rate; three showed no improvement, and nine exhibited improved growth rates. T h e linear growth rates observed during the HGH-androgen treatment period were significantly more (P < 0.001) than those documented when only H G H was administered. During the final 6 months, when no treatment was used, the growth rate fell to the pretreatment mean of 2.7 cmlyear i . SD 1.2. T h e growth rates observed in the three study periods were statistically significant from each other (P < 0.001). 
Increments in Height Age
T h e mean increment in height age (AHA) observed during the first 6 months of H G H treatment was 9.5 months +-SD 2.7. This was significantly less than the gains in HA (14.4 months + SD 3.7) recorded during the period of treatment with H G H and androgen (P < 0.001). I n the last 6-month period when neither H G H or androgen were administered, the mean increment in HA was 1 month (Fig. 2) . 
Rate of Weight Gain
During the H G H treatment period, the rate of weight gain (kilograms per year + SD) was 3.4 * 2.4.
This was significantly less (P < 0.001) than the weight increase of 13 +. 7.0 kg/year which resulted from the combined use of H G H and androgen. I n the last 6 months when neither H G H or androgens were administered, the weight gains were comparable with those observed during H G H treatment (Fig. 3) . T h e increment in weight age (WA) during the 6 months of H G H treatment (months * SD) was 6 + 6.8, which was significantly less ( P < 0.001) than the WA increment observed during H G H and androgen treatment (21 4 
7).

Bone Maturation
T h e effect of each treatment period on bone maturation varied greatly. I n the first 6 months, the mean -advancement i n bone maturation (months t SD) was 12 + 7.7. This was not significantly different from the results observed in the second 6 months of combined HGH-androgen treatment 12 1 12. In the final 6-month study period, the mean increment in bone maturation (ABA) was 8.8 +-6.1 (Fig. 2) . Figure 4 illustrates the ratio of mean ABAIAHA during each study period. This analysis aids in our evaluation of the overall beneficial or harmful effects of the various treatment programs on the rate of bone maturation. T h e mean actual increment in height age in the 6 months of H G H treatment was 9 months, and the increment in bone age was 12 months. T h e ratio ABA/ AHA was 1.3, which is slightly unfavorable. I n the second 6 months when H G H and androgen were administered, the, mean BA (12 months) to HA (14 months) was 0.8, which is a favorable ratio. I n the last 6 months without therapy, the ratio is unfavorable because the mean HA of 1 month is insignificant whereas the mean ABA is 8 months. T h e overall ratio of mean ABA/AHA in the 18 months of treatment was 1.4.
Ratio of Mean ABAIAHA
Sexual Development
Penis growth i n all the males was enhanced by the simultaneous administration of H G H and androgen. I n the girls, mild clitoral enlargement occurred but was insufficient to cause concern.
Physical Appearance
T h e enhanced weight gain and linear growth of these patients were associated with pronounced improvement in their physical appearance (Fig. 5) and psychologic status.
Discussion
T h e data obtained from these clinical studies provide further supportive evidence of a synergistic interaction between HGH and androgen [8, 10, 15, 171 . I n 9 of the 12 children with hypopituitarism participating in our study, linear growth was significantly accelerated by the addition of modest doses of fluoxymesterone to an already standardized H G H regimen. Weight gain was also substantially greater during the period of combined hormone administration. Associated with these changes was a pronounced improvement in appearance, more dramatic than we have previously seen in children with hypopituitarism treated either with H G H or androgen alone. T h e enhanced growth responses documented during the concurrent use of H G H and androgen is in contrast to the reported decline in growth rates seen in hypopituitary patients receiving prolonged, albeit not standardized doses of H G H [l, 2, 141. Therefore, from these observations, it appears that the improved growth, weight gain, and appearance may be attributed to the synergistic effect of H G H and androgen.
T h e interactions between growth hormone and androgens have been extensively examined [8, 10, 13, 15, 171 . Studies carried out in intact animals and humans have shown that androgens increase the pituitary content [4] and enhance pituitary secretion of growth hormone [IO] . In hypopituitary animals [13, 151 and humans [7, 11, 171 , the maximal growth promoting effects of androgens are dependent upon the simultaneous administration of growth hormone. This finding indicates that the peripheral actions of androgens are dependent on an interaction with growth hormone.
T h e ultimate safety and effectiveness of combined HGH-androgen treatment in hypopituitary dwarfs cannot be fully evaluated in the I&month study period which comprises this report. T h e long range effects on bone maturation and possible gonadal function will determine the future role of combined hormonal treatment in hypopituitarism. T h e mean rate of bone maturation during H G H treatment was simi--lar to the value observed during combined treatment. However, statistical analysis of the effects of the different treatment periods on the rate of bone maturation was invalid because of the marked individual variation in response to treatment. An additional concern is the documented increase in bone maturation during the 6-month rest period when neither H G H nor androgen was used. Despite these shortcomings, the overall immediate effect on bone maturation was not clinically unfavorable. Within the 18-month study period, 12 of which consisted of hormone treatment, the mean gain in height age was 23 months, and the mean increase i n bone maturation was 33 months. Since all the patients had markedly retarded bone ages, the advancement i n bone age was compensated for by the accelerated growth rates and the more mature physicaI appearance. Eight of the 12 children achieved heights within 2 SD of the mean in the 18 months of study.
Recent studies in animals indicate that methandrostenolone is a potent anabolic agent with weak androgenic properties. Synergism between this anabolic steroid and growth hormone has already been documented in animals [15] . Clinical trials with oxandrolone, a potent anabolic agent with weak androgenic properties, have not shown unfavorable acceleration of bone maturation [3, 91 in short children with intact pituitaries. In view of the evidence which indicates decreasing growth rates in children on long term H G H therapy, it could be argued that H G H combined with oxandrolone may be a more appropriate protocol for the prepubertal child and that the combination of H G H with potent androgens should be reserved for hypopituitary patients of pubertal age.
Summary
Rates of linear growth and weight gain in hypopituitary patients receiving growth hormone therapy were significantly enhanced by the combined administration of androgen and growth hormone. Within the 18-month period of observation, the gains in height, weight, and physical appearance adequately compensated for the increase in bone maturation.
